News & Views
GE Healthcare Broadens Biopharmaceutical Offerings
GE Healthcare, a unit of General Electric Company is to acquire PAA Laboratories GmbH, a developer and supplier of cell culture media for biomedical research and the fast-growing biopharmaceutical and vaccine manufacturing industry.
Sciences is well known for its expertise in the ‘downstream’ processes of biopharmaceutical manufacturing. Adding ‘upstream’ capabilities will enable us to provide an end-to-end, fully integrated service to our customers.”
The acquisition, which is subject to customary closing conditions including regulatory approvals, is expected to close in Q3 2011. Financial terms were not disclosed.
GE Healthcare President and CEO Kieran Murphy, said: “The acquisition of PAA Laboratories is a significant step forward for our Life Sciences business and for biopharmaceutical manufacturing globally. GE Healthcare Life
Rainer Burian, long-term CEO, PAA Laboratories said: "This is a great opportunity for the professional team of staff at PAA Laboratories and we are very excited to become part of GE Healthcare’s Life Sciences business. The Board of Directors of PAA Laboratories strongly believes that joining such a well-respected and recognised organisation will give us significant opportunities to grow our business further with
new technologies, products and services. The entire PAA Laboratories team looks forward to joining GE.” PAA Laboratories’ cell culture products are manufactured in GMP-certified facilities based in Austria, Australia and Canada and distributed through company subsidiaries and a network of distributors. Employing 215 people revenues were approximately $55 million in 2010. The global demand for media, sera and reagents for cell culture is predicted to grow from $2.3 billion in 2009 to an estimated $3.9 billion by 2015*.
*Source BCC Research “The Dynamic Media, Sera, and Reagent Market in Biotechnology” July 2010
TO FIND OUT MORE CIRCLE NO. 65 News in Brief
Agilent Technologies Inc reported revenues of $1.69 billion for the third fiscal quarter ended July 31, 2011, 22% above one year ago, or 19% excluding the effects of acquisitions and divestitures. Adjusted net income was said to be $276 million, or $0.77 per share (1). Bill Sullivan, Agilent President and CEO, said: “We had another quarter of very good results. Demand for Agilent products remained strong, with key product platforms experiencing solid growth.” Electronic Measurement revenues rose 24% over a year ago, with orders also up by 12%. The Chemical Analysis business saw revenues 17% above those a year ago with orders up 14%. Growth was led by demand in the petrochemical and food markets. Life Sciences also saw revenues rise 21% over last year with orders up by 14%. Pharma and biotech revenues led life sciences growth. Third-quarter ROIC was 25%. Agilent generated $252 million of cash from operations in the third quarter. Net cash at the end of the third quarter was $1 billion. Thermo Fisher Scientific Inc’s second quarter highlights (July 2, 2011), include adjusted earnings per share reflecting 22% growth to a record $0.99, while revenues grew 12% to a record $2.90 billion. The completed acquisition of Dionex created leading chromatography offerings and the
company’s latest acquisition of Phadia is expected to enhance its speciality diagnostics business. Product launches were said to be particularly strong with three new mass spectrometers at this year’s ASMS and a range of oral fluid tests for drugs of abuse screening, while two products, the Thermo Scientific Evolution 200 series UV-Vis spectrophotometer and the Thermo Scientific Dionex ICS-5000 capillary ion chromatography system received R&D 100 Awards. “We also continue to effectively deploy our capital to create shareholder value. We've spent $2.1 billion on acquisitions completed so far this year,” said President and Chief Executive Officer Marc N. Casper. “(and) we deployed $225 million of capital during the quarter to buy back our stock." Medical technology company Carl Zeiss Meditec continued its growth course in the third quarter and achieved a significant increase in revenue compared with the same period of the previous year. "I am particular pleased that this substantial growth in revenue has also had a positive effect on earnings," said Dr Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. The EBIT margin increased from 12.2 percent in the same period of the previous year to 13.6 percent. "This takes us another step closer to achieving our objective of increasing our
margin to 15% by around 2015. All strategic business units and reporting regions are contributing to our growth. This shows that our company is in a stable position," he added. The company has a broad business portfolio, ranging from ophthalmology, through microsurgery, to new applications in radiotherapy. Sartorius started off fiscal 2011 with double-digit growth rates in order intake, sales revenue and profit. “We are currently seeing dynamic growth fuelled by both divisions and all business regions. Compared with the year-earlier quarter, though also slightly below average, we have achieved highly encouraging rates of increase in revenue and profit,” said CEO Dr Joachim Kreuzburg. “Based on our first-quarter results, we confirm our ambitious targets that we have set for the full year of 2011.” In the first three months of 2011, Sartorius increased its sales revenue from the year-ago quarter by 14.4% from 150.4 million euros to 172.1 million euros (in constant currencies: +12.6%). Order intake also rose 15.8% from 167.2 million euros to 193.5 million euros (in constant currencies: +13.9%). Sales revenue grew in all business regions, The gain in profit was even stronger than in sales revenue: Relevant net profit amounted to 10.9 million euros, up from 6.9 million euros compared to the same quarter a year ago.
TO FIND OUT MORE CIRCLE NO. 67
Microbiology company Lab M has appointed Harnek Singh as Export Sales Manager specifically for the Middle East, Eastern Europe, Central Asia and Africa. A microbiologist with extensive commercial experience and a graduate member of the British Institute of Export, he will work alongside fellow Export Sales Manager Veronica Ponnuthurai who supports Western Europe, Asia Pacific and the Americas for the company.
“Lab M is committed to providing comprehensive support for our distributors and partners in all areas of the world as they develop their businesses and extend the use of Lab M products, as well as ensuring the delivery of excellent support to end-users. With his extensive knowledge of sales in the food and clinical industries and major commercial experience in the Middle East, Asia and Africa, Harnek Singh brings great experience and energy to this new role within the export sales team. It is my pleasure to welcome him to the company,” said Phil Large, Lab M’s Sales and Marketing Manager.
TO FIND OUT MORE CIRCLE NO. 66
ITT and YSI Deal Strengthens
Brooks Completes on Nexus Deal
Brooks Automation, Inc has completed the acquisition of California-based Nexus Biosystems, Inc, a specialist in life science automated compound and sample management solutions, for $79 million. Earlier this year, Brooks acquired UK-based RTS Life Science, Ltd another leading supplier of automation systems for the life science industry.
Dr Steve Schwartz, President & CEO of Brooks, said, “We plan to build Brooks Life Science
Systems into the market and innovation leader in Biobanking and Compound Sample Management. With Nexus’ operations on the West Coast and meaningful sales and service locations in Switzerland, Japan and Germany complementing our existing Life Science Systems direct presence on the East Coast and in the UK, we will have broad global reach."
John Lillig, CEO of Nexus Biosystems, commented: "We are very excited about joining the Brooks
team and we are also very much looking forward to joining with our sample management colleagues from RTS. Both Brooks and Nexus have been strong technology innovators.
“Combining the technological and global support strengths of our two companies will help to accelerate the ongoing product development, commercialisation and customer support of our expanding sample management solutions."
TO FIND OUT MORE CIRCLE NO. 68 TA Instruments Acquires Anter Corporation
TA Instruments has acquired Anter Corporation and Anter Laboratories, manufacturers of high performance systems for measuring thermal properties of a wide range of materials. Terry Kelly,
President of TA Instruments said: “ The combination of TA and Anter technologies and the integration into TA’s worldwide sales and technical support organisations will greatly benefit scientists who need
to characterise the thermophysical properties of high temperature materials.” Key products developed by Anter include Laser and Xenon flash systems designed to measure thermal diffusivity and heat
TO FIND OUT MORE CIRCLE NO. 69
Water Business ITT Corporation and privately held YSI Incorporated have formed a definitive agreement for ITT to acquire, via merger, YSI, a leading developer and manufacturer of sensors, instruments, software and data collection platforms for environmental water monitoring. The financial terms of the proposal were not disclosed. YSI had 2010 global revenues of $101 million and employs 390 people at several facilities in the US, Europe and Asia. Completion of the acquisition is expected in the third quarter 2011, pending customary closing conditions and approval from YSI's shareholders.
23
Lab M Expands Export Team
capacity of materials up to 2800°C, dilatometer systems to measure thermal expansion and Guarded Heat Flow meters that measure thermal conductivity of materials in accordance with ASTM standards.
TO FIND OUT MORE CIRCLE NO. 70
Read all the latest News & Views, Articles and New Product Releases Online, visit:
www.labmate-online.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
